

# **Design and Synthesis of Quinazoline Based Compounds as Tyrosine kinase Inhibitors with Anticipated Anti- Proliferative Activity**

Thesis

Presented by

**Samar Mohamed Ahmed Mowafy**

*Msc. in Pharmaceutical Sciences*

*Ain Shams University*

*2012*

Submitted for the partial fulfillment of the

***PhD Degree***

In Pharmaceutical Sciences (Pharmaceutical Chemistry)

*Under the supervision of*

**Dr./ Khaled A. M. Abouzeid**

*Professor of Pharmaceutical Chemistry &  
Head of Pharmaceutical chemistry department  
Ain Shams University*

**Dr./ Nahla A. H. Farag**

*Professor of Pharmaceutical Chemistry  
Head of Pharmaceutical chemistry department  
Misr International University*

**Dr. / Deena S. M. Lasheen**

*Lecturer of Pharmaceutical Chemistry  
Ain Shams University  
Faculty of Pharmacy  
Ain Shams University  
2016*

# Acknowledgements

---

## Acknowledgements

*I am profoundly indebted to **Professor Khaled Abouzid Mohamed Abouzid**, Professor of Pharmaceutical Chemistry and head of pharmaceutical chemistry department, Ain shams university, for suggesting the research point, scientific supervision, innovative ideas, fruitful opinion, invaluable advice, precious suggestions, continuous encouragement and untiring help. I am really sincerely and profoundly indebted to him for his priceless guidance and endless support during the whole work and writing this thesis. He is a dedicated mentor and a role model.*

*It's also a pleasure to express my sincere appreciation and gratitude to **Professor Nahla Ahmed Hassan**, Professor of Pharmaceutical Chemistry and head of Pharmaceutical Chemistry Department, MIU, for her continuous encouragement, tremendous support, endless motivation and enthusiasm. I am heartily grateful to her indispensable opinion, real interest, trust, guidance throughout the whole work.*

*I owe my deepest appreciation and truthful gratitude to **Dr Deena Samy Mohamed Lasheen**, Lecturer of Pharmaceutical Chemistry, for her continuous interest, constant guidance and support during all stages of this work and thesis writing.*

*I would like also to express my sincere thanks to **Dr. Jaebong**, Postdoctoral at Department of Cancer Biology, Dana-Farber Cancer Institute, Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA, USA, for his kindness, continuous encouragement, indispensable assistance, valuable guidance and support throughout the whole work.*

*It's an honor for me to express my sincere appreciation and gratitude to **Professor Nathaneal Gray**, for his supervision, invaluable guidance and mentoring all throughout the time spent in Harvard University, USA.*

*My cordial gratitude extends to **Professor Pasi**, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, for his collaboration in the biological evaluation studies which helped this work to come out in its comprehensive form.*

*I would like also to deeply and truly thank **Dr Allison Galanis**, Postdoctoral at Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, for his invaluable aid in my biology training and **Raymond M. Paranal** for their appreciated efforts in the biology part of this thesis which really enriched this work.*

*I would like to thank **Zainab M Doctor**, Department of Cancer Biology, Dana-Farber Cancer Institute, Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA, USA for her efforts in the biology part of the thesis.*

*I would like also to express my deep thanks to all my lab-mates and all my friends and colleagues in the Department of Department of Cancer Biology, Dana-Farber Cancer Institute and Department of*

## Acknowledgements

---

*Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA, USA, whom I'll always remember for their continuous guidance, friendly assistance and invaluable advices. I am truly grateful for their guiding me to learn a lot about practical chemistry and biology.*

*I can't forget to express my sincere gratitude to the Fulbright Commission in Egypt and the state department for offering me the opportunity to perform my studies abroad, and for the financial funding in Harvard Medical School and all throughout my stay in the USA.*

*Finally, I am profoundly indebted to my parents, my sister and my two brothers for their endless patience, understanding, encouragement and support all throughout the whole long way.*

---

## Pre-requisite Predoctoral Courses and Exams

In addition, to the work presented in the thesis, the candidate has attended and passed the following Pre-requisite predoctoral courses:

- Pharmaceutical chemistry
- Drug design
- Stereochemistry
- Selected topics

Moreover, the candidate has passed a comprehensive exam in organic and Pharmaceutical chemistry and presented a research proposal with the title of “**Design, Synthesis and Evaluation of Novel Tyrosine Phosphatase Inhibitors**”.

# Contents

---

## Contents

Acknowledgements .....	i
Contents.....	iv
List of Figures .....	vi
List of Tables.....	ix
List of Abbreviations .....	x
Abstract.....	xiv
1. Introduction .....	1
1.1. Carcinogenesis .....	1
1.2. Causes of cancer .....	1
1.3. Mechanism of cancer formation.....	2
1.3.1. Activation of proto-oncogenes .....	2
1.3.2. Inactivation of tumor suppression genes .....	2
1.4. Treatment of cancer .....	3
1.4.1 Traditional cancer treatments .....	3
1.4.2 Targeted cancer treatments .....	8
1.5. Protein kinases.....	10
1.5.1. Overview .....	10
1.5.2. Structural features of protein kinases .....	11
1.5.3. Types of kinase inhibitors .....	12
1.5.4. Tyrosine specific kinases .....	17
1.5.5. Receptor tyrosine kinases .....	17
1.5.6. Epidermal growth factor receptors tyrosine kinases (EGFR TKs) and their inhibitors .....	18
2. Rationale and design:.....	44
2.1. Synthetic Schemes adopted to prepare the target compounds:.....	49
2.2. Molecular Modeling.....	52
3. Results and Discussion.....	55
3.1. Chemistry .....	55
3.1.1. Scheme 1.....	55

# Contents

---

3.1.2.	Scheme 2:.....	56
3.1.3.	Scheme 3 and 4.....	62
3.2.	Biological Evaluation.....	72
3.2.1.	In vitro EGFR tyrosine kinase activity.....	72
3.2.2.	In vitro HER2 tyrosine kinase activity.....	84
3.3.	Molecular Modeling studies: .....	87
3.4.	ADMET study:.....	91
3.4.1.	ADMET study results: .....	92
4.	Final Conclusion.....	96
5.	Experimental.....	99
5.1.	Chemistry .....	99
5.1.1.	Materials and instrumentation .....	99
5.1.2.	Synthesis .....	100
5.2.	Biological Evaluation .....	123
5.2.1.	Materials and Methods.....	123
6.	References.....	133

# List of Figures

---

## List of Figures

Figure 1: Protein kinase catalytic domain bound to ATP with src .....	12
Figure 2: Four types of reversible binding mode of kinase inhibitors. ....	14
Figure 3: Clinically approved small molecule kinase inhibitors .....	16
Figure 4: Classification of clinically approved small molecule kinase inhibitor according to mechanism of action .....	16
Figure 5: The main EGFR family signaling pathways .....	19
Figure 6: Crystallographic structure of EGFR (PDB code: 2GS2) .....	20
Figure 7: EGFR active versus inactive conformations : (PDB code: 2GS2 (active) and 1XKK (inactive)). .....	21
Figure 8: Active site of EGFR with the position of different key mutations (PDB 2G2S).....	21
Figure 9: Mutations associated with increased drug sensitivity .....	22
Figure 10: (A): EGFR mutation L858R, (PDB code: 2ITV), (B): The exon 19 deletion mutant EGFR... 23	
Figure 11: Mutations associated with drug resistance .....	24
Figure 12. Schematic representation of anticancer drugs acting on EGFR–HER2 pathways .....	26
Figure 13. Binders inside the ATP pocket. Summary of active-site modulators .....	31
Figure 14: Pharmacophore Model. Traditional pharmacophore model for type I inhibitors, modified Traxler .....	35
Figure 15: The binding modes of gefitinib (14) to ATP of EGFR TK. Hydrogen bonds are indicated by dashed lines.....	36
Figure 16: Stereoview of the inhibitor binding site and nearby residues from EGFR/erlotinib (15) .....	37
Figure 17. Lapatinib (GW572016) (33) binding in the ATP binding site of EGFR. ....	39
Figure 18: schematic interactions of afatinib (22) with EGFR .....	40
Figure 19: schematic interactions of dacomitinib (37) with EGFR T790M .....	40
Figure 20: SAR of 4-anilinoquinazoline binding to EGFR .....	42
Figure 21: Representative substituents at C6 position of the quinazoline EGFR inhibitors .....	43

## List of Figures

---

Figure 22: Cumulative number of small molecule kinase inhibitor publications since 1950 [49] .....	44
Figure 23: A: structure of EGFR inhibitor 38, B: Docking of compound 38 in the ATP binding site of EGFR TK.....	46
Figure 24: Design strategy of target compounds .....	48
Figure 25: Synthetic pathway for compound 39.....	55
Figure 26: Different synthetic pathways for synthesis of compound B.....	56
Figure 27: Mechanism of synthesis of N,N-dimethylimidoforamamide derivative II .....	57
Figure 28. Synthesis of 4-aminoquinazoline in two step reaction as explained in text. ....	58
Figure 29. Mechanism of the synthesis of 6-nitro-3-phenylquinazolin-4(3H)-imine.....	59
Figure 30. Mechanism of the synthesis of 4-anilinoquinazolines.....	60
Figure 31: Synthesis of 4-anilinoquinazoline using one pot reaction of triethyl orthoformate .....	61
Figure 32: $^1\text{H}$ – $^{15}\text{N}$ HSQC of Va.....	63
Figure 33: $^1\text{H}$ – $^{13}\text{C}$ HSQC of compound VIa.....	64
Figure 34: $^1\text{H}$ – $^{15}\text{N}$ HSQC of VIa .....	64
Figure 35: General synthesis of substituted ureas.....	65
Figure 36: Synthesis of unsymmetrically substituted ureas using phosgene .....	66
Figure 37: Synthesis of unsymmetrically substituted ureas using N,N'-carbonyldiimidazole (CDI).....	66
Figure 38: Synthesis of unsymmetrically substituted ureas using isocyanates.....	66
Figure 39: Proposed pathway for synthesis of compound 50 using two step reactions.....	67
Figure 40: synthesis of substituted urea derivatives using carbamates.....	67
Figure 41: General synthesis of thiourea compounds .....	70
Figure 42: Assay of percent inhibition of EGFR enzyme at corresponding compound concentrations .....	77
Figure 43: Effect of inhibition of phosphorylation of EGFR, AKT and ERK after incubation with 1 and 10 $\mu\text{M}$ of compound VIc against Ba/F3 WT and Ba/F3 L858R cell lines.....	78
Figure 44: Effect of inhibition of phosphorylation of EGFR after incubation for 6h with 1 $\mu\text{M}$ of corresponding compounds (Va, VIa and gefitinib(14)) against Ba/F3 WT and Ba/F3 L858R cell lines ...	79
Figure 45: Assay of growth percent of double mutant del19/T790M Ba/F3 cells after adding 10 $\mu\text{M}$ of compounds, and plotted relative to DMSO.....	80



## List of Figures

---

Figure 46: Assay percent growth after treating Ba/F3 double mutant L858R/T790M with 10 uM of compounds and plotted relative to DMSO.....	80
Figure 47: PC9 cells were treated with compounds (Vc, VIc, XVb, XIVb and gefitinib (14)) at the indicated concentrations, and viable cells were measured after 72 hours of treatment and plotted relative to untreated controls.....	82
Figure 48: PC9-GR4 cells were treated with compounds (Vc, VIc, XVb, XII, XIVb and gefitinib .....	82
Figure 49: Effect of inhibition of phosphorylation of EGFR and AKT after incubation for 6h with 10uM of corresponding compounds (Vc, VIc, XVb, XII, XIVb and gefitinib (14)) against PC9 cell lines .....	83
Figure 50: Effect of inhibition of phosphorylation of EGFR and AKT after incubation for 6h with 10uM of corresponding compounds (Vc, VIc, XVb, XII, XIVb and gefitinib (14)) against PC9-GR4 cell lines	84
Figure 51: Assay of percent inhibition of HER2 enzyme at corresponding compound concentrations .....	86
Figure 52: BT-474 cells were treated with compounds (XII, XIVb, XVb and gefitinib (14), lapatinib (33)) at the indicated concentrations, and viable cells were measured after 72 hours of treatment and plotted relative to untreated controls.....	86
Figure 53: (A): binding mode of lapatinib in the ATP binding site showing two hydrogen bonds with Met793, (B): The superimposition between the top docking pose and original crystallographic geometry of lapatinib (30) .....	88
Figure 54: Proposed binding modes of compound VIIIId (A) and compound IXc (B) .....	89
Figure 55: Proposed binding mode of compounds IXb (A) and Xb (B).....	90
Figure 56: Proposed binding mode of compounds XIVb on crystal structure (PDB 3W2O).....	91
Figure 57: Plot of human intestinal absorption (HIA) and blood brain barrier plot for the newly synthesized compounds .....	94
Figure 58: Z'-LYTE® principle Illustration.....	124

## List of Tables

---

### List of Tables

Table 1. Docking scores of the top-ranked poses of the modeled molecules .....	53
Table 2. The effect of newly synthesized urea derivativess (Va-c, VIa-c, XI, XII, VIIIa-d, XIVa,b) on EGFR enzymatic activity and antiproliferation against Ba/F3expressing EGFR WT and L858R.....	72
Table 3. The effect of thiourea derivatives (IXa-e, XVa,b, Xa,b, XVI) on EGFR enzymatic activity and antiproliferation against Ba/F3expressing EGFR WT and L858R .....	74
Table 4: Antiproliferative activity of XII, XIVb, XVb on transformed Ba/F3 cells .....	79
Table 5: Antiproliferative activity of compounds on transformed PC9 and PC9-GR4.....	81
Table 6: Assay of the effect of compounds on HER2 enzyme activity and antiproliferation against BT-474 cells .....	85
Table 7: Computer aided ADMET screening of the synthesized compounds.....	94
Table 8: Activity of compound XIVb compared to gefitinib (14) against different wild and resistant cell lines .....	97

# List of Abbreviations

---

## List of Abbreviations

3D: 3-Dimensional

2D: 2-Dimensional

Å: Angstroms

A-loop: Activation loop

Abl: Abelson tyrosine kinase

Arg: Arginine

Asn: Asparagine

Asp: Aspartate

Asp-Phe-Gly : Aspartate-Phenyl alanine-Glycine

AT: Adenine thymine

ATP: Adenosine-5'-triphosphate

BBB: Blood brain barrier level

BSA: Bovine serum albumin

CYP2D6: Cytochrome P450 2D6

DFG: Aspartate-Phenylalanine-Glycine sequence

DIPEA: N,N Diisopropylethylamine

DMA: Dimethylacetal

DMF: Dimethyl formamide

DMSO: Dimethylsulfoxide

DNA: Deoxyribonucleic acid

EGFR: Epidermal growth factor receptor

FAK: Focal adhesion kinase

FDA: Food and Drug Administration

FGFR: Fibroblast growth factor receptor

## List of Abbreviations

---

FRET: fluorescence resonance energy transfer

G-loop: glycine rich loop

Glu: Glutamate

Gly: Glycine

HIA: Human intestinal absorption

HIV: Human immunodeficiency virus

HPLC: High-performance liquid chromatography

IC50: Half maximal inhibitory concentration

Ig: Immunoglobulin

L858R: Leucine858Arginine

Lck: Lymphocyte-specific protein tyrosine kinase

Leu: Leucine

Lys: Lysine

mAB: Monoclonal antibody

MAPK: Mitogen activated protein kinase

MEK: Map kinase kinase

Met: Methionine

Mp: Melting point

MS (ESI): Electrospray ionization mass spectrometry

NRTK: Non-receptor tyrosine kinase

NMR: Nuclear magnetic resonance

NSCLC: Non-small cell lung cancer

NRTK: Non- recptor tyrosine kinase

PBS: Phosphate buffered saline

PDB: Protien Data Bank

PDGFR: Platelet derived growth factor receptor

PI3K: Phosphatidylinositol-3-kinase

## List of Abbreviations

---

ppm: part per million

Pred: predicted

PSA: Polar surface area

PPB: Plasma protein binding

RMSD: Root mean square deviation

RNA: ribonucleic acid

RPMI: Rosewell Park Memorial Institute

RT: room temperature

RTK: receptor tyrosine kinase

SAR: Structure activity relationship

Ser: serine

S phase: Synthesis phase

SRC: Sarcoma (Schmidt-Ruppin A-2) Viral Oncogene

S/TKs: Serine-threonine kinases

T790M: Threonine790Methionine

TBST: Tris-buffered saline, 0.1% Tween 20

TEOF: triethyl orthoformate

TFA: Trifluoroacetic acid

TGF: Transforming growth factor

THF: Tetrahydrofuran

TK: Tyrosine Kinase

TKI: Tyrosine kinase inhibitors

TLC: Thin Layer Chromatography.

TMS: Tetramethylsilane

TNF: Tumor necrosis factor

## List of Abbreviations

---

Val: valine

VEGFR: Vascular Endothelial growth factor

**Abstract**

*Title of thesis:*

**Design and Synthesis of Quinazoline Based Compounds as  
Tyrosine kinase Inhibitors with Anticipated Anti-Proliferative  
Activity**

*Name of candidate:*

**Samar Mohamed Ahmed Mowafy**

*Senior Teaching Assistant of Pharmaceutical Chemistry*

*Misr International University*

*Thesis supervised by:*

**Prof. / Khaled A. M. Abouzid**

**Prof. / Nahla A. H. Farag**

**Dr. / Deena S. M. Lasheen**